Therapeutic approaches in the management of behavioral and psychological symptoms of dementia in the elderly

More than 90% of pa tients with dementia will eventually develop behavioral and psychological symptoms of dementia, which in clude agitation, psychosis, and mood disorders. The Vancouver Coastal Health Authority has recently produced a guideline for the assessment, nonpharmacological treatment, and pharmacological treatment of ag gression and agitation in patients with dementia in acute or residential care. The guideline reflects research that has found atypical antipsy chotic agents to be effective for aggressive forms of behavioral and psychological symptoms of dementia. Pharmacological alternatives to atypical antipsychotic medications that have also been found to be effective in clude typical antipsychotic medication, cholinesterase inhibitors, antidepressants, and anticonvulsants. Dementia is a devastating illness for both patients and their families. A patient with de mentia has memory loss and at least one other impairment: aphasia, apraxia, agnosia, or disturbance in executive functioning. Of those patients with dementia, more than 90% will eventually develop behavioral and psychological symptoms of dementia (BPSD). These include agitation, psy chosis, and mood disorders. After co-occurring medical conditions are ruled out, initial management of BPSD consists of nonpharmacological ap proaches, and then pharmacological ones when absolutely needed. A guideline recently produced by the Vancouver Coastal Health Authority (VCH) helps clinicians tailor treatment specifically for the individual patient and weigh the benefit of an intervention carefully against the risk. The VCH guideline was developed by geriatric psychiatrists and pharmacists within the region and is endorsed by the Regional Pharmacy and Therapeutics Committee, the Health Authority Medical Advisory Council, and the VCH Professional Practice Directors. The VCH guideline is intended to reflect evidencebased practice, but it should not be taken as absolute guidance in every situation. It may not be entirely appropriate in a different setting or health authority, and may be subject to revision.The biopsychosocial approach recommended when managing BPSD requires investigating medically reversible symptoms before initiating atypical antipsychotic therapy. Behavioral and psychological symptoms of dementia Agitation, psychosis, and mood disorders are the core concerns for cliniTherapeutic approaches in the management of behavioral and psychological symptoms of dementia in the elderly A guideline produced by the Vancouver Coastal Health Authority describes how to assess patients in acute and residential care and identify the best nonpharmacological and pharmacological options for treating agitation, psychosis, and mood disorders. Natalie Drouillard, MD, Akber Mithani, MD, Peter K.Y. Chan, MD, FRCPC Dr Drouillard is a resident in the Department of Psychiatry at the University of British Columbia. Dr Mithani is director of the Primary Care of the Elderly Research Group in the Department of Family and Community Medicine, Providence Health Care. He is also a clinical associate professor in the Department of Psychiatry and associate in the Department of Family Practice at UBC. Dr Chan is a clinical professor in the Department of Psychiatry at UBC. He is also a geriatric and consultation liaison psychiatrist at Vancouver General Hospital. This article has been peer reviewed. 90 BC MEDICAL JOURNAL VOL. 55 NO. 2, MARCH 2013 www.bcmj.org cians managing patients with BPSD. Depression occurs in 20% of patients with Alzheimer disease and is more frequent and persistent in those with vascular dementia. Psychosis in the form of hallucinations and delusions occurs in 25% of patients with dementia. Delusions are usually non-bizarre and often persecutory regarding theft. Agitation occurs in 20% of outpatients and 40% to 60% of inpatients, including those in residential care settings.Agitation can be aggressive and involve restlessness/pacing, verbal insults, shouting and physical aggression, or nonaggressive and involve wandering, exit-seeking behavior, and disruptive vocalizations. BPSD can be distressing to the patient and can increase caregiver burden and lead to earlier institutionalization. A management strategy that begins with patient assessment and includes the carefully monitored use of atypical antipsychotic agents can offer some relief to patients and their caregivers. Assessment and tracking of BPSD The first priority in assessment should be to ensure the safety of the patient and caregiver. The symptoms and signs should be documented as des cribed in the VCH guideline, using an ABC approach that focuses on Antecedents, Behaviors, and Consequences. Caregivers should note specifically what type of behavior (e.g., verbal, physical, sexual) results from what type of antecedent (e.g., morning care routine, meals, ambulation), or if the behavior is unprovoked. Standardized tools can be useful when tracking behaviors of patients with dementia. The Dementia Observation System is available online on the Canadian Academy of Geriatric Psychiatry’s website http://bit.ly/WEj 9WO. This chart could be completed on admission to a long-term care facility, or at any stable point in a patient’s life. In addition, the patient’s baseline alertness, cognitive function, and capacity to perform activities of daily living should be documented. A tool such as the Behavioral Vital Signs chart can be used to track symptoms and signs, and the patient’s response to interventions over time. Caregivers can use the chart to report on agitation, delusions, hallucinations, depression/ anxiety, manic states, sleep/wake cy cle, and apathy over a 2-week period to provide the interdisciplinary care team with more information prior to the assessment. The biopsychosocial model commonly used in psychiatry for understanding illness is useful for BPSD. Many biological factors can contri bute to the development of de mentia symptoms, including delirium, pain or discomfort, infection, metabolic issues, neuropsychiatric issues, poly pharmacy, substance abuse or withdrawal, or dietary and drug interactions. Every effort should be made to thoroughly investigate medically re versible causes of these symptoms to ensure the best treatment for the pa tient suffering with dementia. This may require ordering a panel of laboratory tests (CBC, electrolytes, urea, creatinine, phosphate, magnesium, calcium, albumin, liver profile, liver function, TSH, vitamin B12, PSA, urinalysis) and radiological investigations (CT head, KUB X-ray, chest X-ray, bone X-rays). Psychosocial issues influencing the development of BPSD are also numerous. Communication factors include problems with hearing or sight and language barriers. Examples of environmental factors are excessive or inadequate stimulation; unmet dietary needs or acknowledgment of preferences; and inappropriate room temperature, clothing, furniture, or medical equipment. Family factors include conflict, caregiver strain, fi nan cial concerns, and absence or loss of family supports. Addressing rever sible factors is of paramount importance. Nonpharmacological intervention Despite evidence showing that physicians do not usually use nonpharmacological interventions first, and that in an emergency situation pharmacological therapy may be needed, the general principle of investigating the Therapeutic approaches in the management of behavioral and psychological symptoms of dementia in the elderly A management strategy that begins with patient assessment and includes the carefully monitored use of atypical antipsychotic agents can offer some relief to patients and their caregivers. 91 www.bcmj.org VOL. 55 NO. 2, MARCH 2013 BC MEDICAL JOURNAL patient’s symptoms thoroughly with a biopsychosocial approach still holds. A psychosocial care plan that emphasizes “interest, social activity, and comfort” should be created. During treatment with pharmacological agents, the patient’s circumstances should continue to be optimized. A pharmacist should also be consulted to assess medication-related effects. Given the complexity of the work up, the VCH guideline discourages telephone orders to initiate drug therapy. Instead, the guideline advises that a physical assessment of the patient be completed, and encourages the gathering of collateral information and laboratory results prior to initiating treatment. Evidence for atypical antipsychotic medication for BPSD Atypical antipsychotic medication has the largest evidence base for efficacy in treating BPSD. However, the available data are rampant with inconsistent results and are based on small RCTs with limitations, short durations (typically 12 weeks), prominent placebo response rates (30% to 40%), and highly selected patients. The evidence is strongest for treatment of aggressive BPSD and weaker for nonaggressive forms. Most studies have in cluded only patients with Alzheimer disease and vascular dementia, making extrapolation to other forms of dementia difficult. The specific be haviors of wandering, exit-seeking, and disruptive vocalizations are un likely to respond to pharmacological treatment. The number needed to treat (NNT) with atypical antipsychotic medication to improve BPSD ranges from 5 to 14. There is no good evidence that atypical antipsychotic medication improves the patient’s functional abilities or quality of life, or reduces caregiving time needed, although improvements can be seen for some patients anecdotally. Risks of atypical antipsychotic therapy Risks associated with atypical anti psychotic medication are also important to consider. There has been in complete reporting of side effects in randomized controlled trials and risks after 12 weeks of use are largely unknown. Adverse drug reactions include urinary tract infections (number needed to harm, NNH = 25), extra pyramidal symptoms, confusion, falls, hypotension, ECG abnormalities and peripheral edema (NNH = 20), abnormal gait (NNH = 13), and tardive dys kinesia, anticholinergic toxicity, and somnolence (NNH = 10). Other ad verse reactions include respiratory tract infections, hyperglycemia, weight gain, and cognitive decline. The increased risk of mortality that prompted the Health Canada June 2005 warning against the use of atypical antipsychotic medication in pa tients with dementia is based on two meta-analyses. The warning was unclear about whether pre-existing factors affect the risk of death, and provided insufficient information on the cause of death. NNH was found to be 100 and results were pooled for risperidone, olanzapine, quetiapine, and aripiprazole. Health Canada has also warned of an increased risk of cerebrovascular events with risperidone (October 2002) and olanzapine (March 2004). These warnings were based on an indepen dent meta-analysis that showed the NNH was 71, with a 2.2% occurrence of cerebrovascular events in the study population over a 0.8% risk in the general population. Again, it is un clear if pre-existing factors affected risk. Also, the overall rate of cardiovascular events did not differentiate between TIA and stroke. Despite the numerous study limitations and the known side effects of atypical antipsychotic medications, nonpharmacological interventions may not be enough to ease patient distress and caregiver burden. The VCH guideline recommends that atypical anti psychotic medications be used when Therapeutic approaches in the management of behavioral and psychological symptoms of dementia in the elderly The VCH guide line recommends that atypical anti psychotic medications be used when “there is a significant risk of harm to the patient or others, or when agitation or aggressive symptoms are persistent, recurrent, or severe enough to cause significant suffering and distress, or significant interference with care.” 92 BC MEDICAL JOURNAL VOL. 55 NO. 2, MARCH 2013 www.bcmj.org “there is a significant risk of harm to the patient or others, or when agitation or aggressive symptoms are persistent, recurrent, or severe enough to cause significant suffering and distress, or significant interference with care.” The NNT has been estimated from 9 to 25 when the risks of these medications are taken into account. However, decisions must be made at an individual patient level and it re mains difficult to predict which pa tients will benefit and which may be harmed. Initiating atypical antipsychotic therapy Prior to initiating use of atypical antipsychotic medication, the prescriber should inform the family or substitute decision-maker about treatment options, risks, and benefits, obtain consent, and document the conversation. Currently, Health Canada has ap proved risperidone for “short-term symptomatic management of inappropriate behavior due to aggression and/ or psychosis” in dementia. A Coch rane review found evidence for risper idone and olanzapine to treat aggression, and for risperidone to treat psy chosis. Patients with Lewy body and Parkinson disease are especially susceptible to extrapyramidal symptoms and hence quetiapine is typically recommended for these individuals. When initiating atypical antipsychotic medication, begin at a low dose (e.g., risperidone 0.25 mg per day, olanzapine 2.5 mg per day, or quetia pine 12.5 to 25 mg per day). As some adverse drug reactions are dose-related (e.g., hypotension, gait disturbance, extrapyramidal side effects, somnolence, and anticholinergic side effects), “aim for the lowest effective maintenance dose.” Target doses have not been studied in detail, but consider doses in the range of risperidone 0.5 to 1.5 mg per day, olanzapine 5 to 10 mg per day, or quetiapine 50 to 200 mg per day. These medications can be given once or twice daily; any more often is probably unnecessary. As-needed dosing of atypical anti psychotic medication has not been studied in terms of efficacy or harm and has not been compared to other commonly used as-needed medication such as benzodiazepines. The VCH guideline outlines four situations for as-needed dosing of atypical antipsychotic medication: “to determine the need for a maintenance dose, during the dose titration phase in conjunction with regular dosing, in advance of unavoidable activities known to trigger significantly aggressive or agitated behavior, and for anticipated but intermittent behaviors.” The rationale for using single doses of atypical antipsychotic medication should be documented, as should a specific indication for use. Assessment of asneeded doses should be ongoing to determine if the regular dosing should be increased. Monitoring atypical antipsychotic therapy Monitoring has been previously des cribed, and follow-up intervals at 1 week post initiation of treatment and 10 days after dose changes have been recommended. The VCH guideline suggests that a decision regarding effectiveness should be made by 8 weeks. Physical assessments should monitor for movement disorders (extrapyramidal symptoms and tardive dyskinesia). Although moni toring for hyperglycemia, dyslipidemia, and weight gain has also been recommended, clinical relevance in the patient with BPSD has not been determined. Atypical antipsychotic medication should be reduced or discontinued if the QTc interval becomes prolonged. Withdrawing medications When considering the duration of atypical antipsychotic therapy in BPSD, it is important to note that most randomized controlled trials have not extended beyond 12 weeks, and therefore efficacy and harm beyond this time are not well known. At least one study has shown an increase in mortality when using atypical antipsychotic medication at 3-year followup, but the study limitations are nu merous. In many patients, symptoms fluctuate as part of the disease and may attenuate as the disease progresses. For example, in patients with Al zheimer disease, hallucinations may resolve after a few months, but delusions, aggression, and agitation can persist for longer. Given the side effects of these medications, it is reasonable to lower or discontinue their use after a period of stability. For instance, Canadian guidelines for long-term care recommend periodic attempts to taper and discontinue atypical antipsychotic medication. The authors of the VCH guideline have created an algorithm with a suggested tapering schedule to begin after 3 to 6 months of behavioral stability. The prescriber is advised to review a recent behavior log and if the behavior is acceptable, lower the atypical antipsychotic by the smallest dosage possible. The behavior can be revisited in 2 to 4 weeks and the dosage tapered again if the behavior remains stable. Despite these recommendations, some patients will likely need long-term therapy with atypical anti psychotic medication, especially those with more severe symptoms. Pharmacological alternatives Typical antipsychotic medications can be useful in patients who refuse oral preparations and require intramuscular injection. Haloperidol and Therapeutic approaches in the management of behavioral and psychological symptoms of dementia in the elderly 93 www.bcmj.org VOL. 55 NO. 2, MARCH 2013 BC MEDICAL JOURNAL loxapine can be used for short-term treatment, and zuclopenthixol intermediate-acting depot (Acuphase) can be used for patients with persistent and dangerous BPSD. Benzodiazepines are not typically recommended for the elderly because they increase risk of falls, fractures, and confusion. When caring for individuals who are bed-bound and resistive to nursing procedures, fastacting benzodiazepines such as loraz epam can aid in the completion of care without oversedating the patient. Short-term use may sometimes be warranted, but long-half-life benzodiazepines such as diazepam should be avoided. Although the evidence for use of trazodone is not clear, it has been shown to be helpful in patients with agitation, anxiety, and sleep disturbance. Cholinesterase inhibitors can reduce apathy, depression, and aberrant motor behavior, and can be particularly useful in Lewy body disease. Memantine is indicated in treatment of moderate to severe Alzheimer disease, either by itself or in conjunction with a cholinesterase inhibitor. It has also been shown to stabilize agitation and irritability in some patients, or even prevent the emergence of BPSD, but may worsen agitation in a few. Antidepressants are another option. Symptoms can improve with SSRIs, supporting the explanation of BPSD as due in part to frontal serotonin dysfunction. Citalopram and sertraline have the best evidence for use in pa tients with dementia. The patient should be monitored for syndrome of inappropriate antidiuretic hormone secretion after SSRI therapy begins, and a baseline sodium excretion value should be obtained. There is also evidence for using anticonvulsants in BPSD. However, studies of valproic acid, carbamaze pine, oxcarbazpine, and gabapentin have shown conflicting results. Gaba pentin dosing must be reduced in those with renal impairment. Medications used for BPSD that have a poor evidence base include analgesics (unless there is a clear pain syndrome, or incident pain during personal care), cannabinoid receptor agonists (nabilone and dronabinol), and hormonal treatments (anti andro gen agents, melatonin, and ginkgo biloba extract). Conclusions Behavioral and psychological symptoms of dementia eventually occur in more than 90% of patients with de mentia and can severely affect the patient’s quality of life and increase caregiver stress. The Vancouver Coas tal Health Authority has recently produced a guideline that addresses the assessment and management of BPSD with atypical antipsychotic medication. The guideline recommends evaluating patient’s symptoms within a biopsychosocial model and treating all reversible causes of BPSD prior to initiating pharmacological therapy. Clinicians should be aware that aggressive forms of BPSD are more responsive to atypical antipsychotic medication than are nonaggressive forms, and that other forms of pharmacotherapy can also be useful. Competing interestsNone declared. References1. American Psychiatric Association. Diag-nostic and statistical manual of mentaldisorders. 4th rev ed. Washington, DC:APA;2000: 147-171.2. Steinberg M, Shao H, Zandi P, et al. Pointand 5-year period prevalence of neu-ropsychiatric symptoms in dementia:The Cache County Study. Int J GeriatrPsychiatry 2008;23:170-177.3. Aalten P, de Vugt ME, Lousberg R, et al.Behavioral problems in dementia: A fac-tor analysis of the neuropsychiatric inven-tory. Dement Geriatr Cogn Disord 2003;15:99-105.4. Atypical antipsychotic agents, guidelinefor use as part of the management strat-egy of behavioural and psychologicalsymptoms of dementia (BPSD). Acces-sed 10 April 2011. www.careforelders.ca/VCHAtypicalsWithdrawal(Version_Oct_25_2010).pdf.5. Lyketsos CG, Steinberg M, Tschanz JT,et al. Mental and behavioral disturbancesTherapeutic approaches in the management of behavioral and psychological symptoms of dementia in the elderly Clinicians should be aware thataggressive forms of BPSD are moreresponsive to atypical antipsychoticmedication than are nonaggressiveforms, and that other forms ofpharmacotherapy can also be useful. 94 BC MEDICAL JOURNAL VOL. 55 NO. 2, MARCH 2013 www.bcmj.org in dementia: Findings from the CacheCounty Study on memory in aging. Am JPsychiatry 2000;157:708-714.6. Ballard CG, Patel A, Solis M, et al. A one-year follow-up study of depression indementia sufferers. Br J Psychiatry 1996;168:287-291.7. Ballard C, Corbett A, Chitramohan R, etal. Management of agitation and aggres-sion associated with Alzheimer’s dis-ease: Controversies and possible solu-tions. Curr Opin Psychiatry 2009;22:532-540.8. Burns A, Jacoby R, Levy R. Psychiatricphenomena in Alzheimer’s disease. IV:Disorders of behavior. Br J Psychiatry1990;157:86-94.9. Margallo-Lana M, Swann A, O’Brien J, etal. Prevalence and pharmacological man-agement of behavioral and psychologicalsymptoms amongst dementia sufferersliving in care environments. Int J GeriatrPsychiatry 2001;16:39-44.10. Dyer C, Pavlik VN, Murphy K, et al. Thehigh prevalence of depression anddementia in elder abuse or neglect. J AmGeriatr Soc 2000;48:205-208.11. Passmore MJ, Gardner DM, Polak Y, etal. Alternatives to atypical antipsychoticsfor the management of dementia-relatedagitation. Drugs Aging 2008;25:381-398.12. Canadian Coalition for Seniors’ MentalHealth. National guidelines for seniors’mental health: The assessment andtreatment of mental health issues in long-term care homes. Can J Geriatrics 2006:9:S59-64. Accessed 8 January 2013.www.ccsmh.ca.13. Cohen-Mansfield J. Nonpharmacologicinterventions for inappropriate behaviorsin dementia: A review, summary, and cri-tique. Am J Geriatr Psychiatry 2001;9:361-381.14. Salzman C, Jeste D, Meyer RE, et al. Eld-erly patients with dementia-relatedsymptoms of severe agitation and ag -gression: Consensus statement on treat-ment options, clinical trials methodology,and policy. J Clin Psychiatry 2008;69:889-898.15. Canadian Association of Geriatric Psychi-atry. Behavioral Vital Signs (BVS) Tool.Accessed 8 January 2013. www.cagp.ca/resources/Documents/Module%202%20-%20BVS%20Tool.pdf.16. Kunik ME, Walgama JP, Snow L, et al.Documentation, assessment, and treat-ment of aggression in patients withnewly diagnosed dementia. AlzheimerDis Assoc Disord 2007;21:115-121.17. Gauthier S, Cummings J, Ballard C, et al.Management of behavioral problems inAlzheimer’s disease. Int Psychogeriatr2010;22:346-372.18. Ballard C, Waite J. The effectiveness ofatypical antipsychotics for aggressionand psychosis in Alzheimer’s disease.Cochrane Database Syst Rev 2006(1):CD003476.19. Schneider LS, Dagerman K, Insel PS. Effi-cacy and adverse effects of atypicalantipsychotics for dementia: Meta-analy-sis of randomized, placebo-controlled tri-als. Am J Geriatr Psychiatry 2006;14:191-210.20. Sultzer DL, Davis SM, Tariot PN, et al.Clinical symptom responses to atypicalantipsychotic medications in Alzheimer’sdisease: Phase 1 outcomes from theCATIE-AD effectiveness trial. Am J Psy-chiatry 2008;165:844-854.21. Lee PE, Fischer HD, Rochon PA, et al.Published randomized controlled trials ofdrug therapy for dementia often lackcomplete data on harm. J Clin Epidemiol2008;61:1152-1160.22. Health Canada. Health Canada advisesconsumers about important safety infor-mation on atypical antipsychotic drugsand dementia. Accessed 10 April 2011.www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2005/2005_63-eng.php.23. Schneider LS, Dagerman KS, Insel P. Riskof death with atypical antipsychotic drugtreatment for dementia: Meta-analysisof randomized placebo-controlled trials.JAMA 2005;294:1934-1943.24. Kuehn BM. FDA warns antipsychoticdrugs may be risky for elderly. JAMA2005:293:2462.25. Herrmann N, Lanctot KL. Do atypicalantipsychotics cause stroke? CNS Drugs2005;19:91-103.26. Alexopoulos GS, Streim J, Carpenter D,et al. Using antipsychotic agents in olderpatients. J Clin Psychiatry 2004;65(suppl2):21-41.27. Schneeweiss S, Avorn J. Antipsychoticagents and sudden cardiac death—howshould we manage the risk? N Engl JMed 2009;360:294-296.28. Ballard C, Hanny MT, Douglas S, et al.The dementia antipsychotic withdrawaltrial (DART-AD): Long-term follow-up of arandomized placebo-controlled trial.Lancet Neurol 2009;8:151-157.29. Haupt M, Kurz A, Janner M. A 2-year fol-low-up of behavioral and psychologicalsymptoms in Alzheimer’s disease. De-ment Geriatric Cogn Disord 2000;11:147-152.30. Ballard CG, Thomas A, Fossey J, et al. A3-month, randomized, placebo-controlled,neuroleptic discontinuation study in 100people with dementia. J Clin Psychiatry2004;65:114-119.31. Passmore MJ. Approach to the manage-ment of dementia-related behavioralproblems. Geriatr Aging 2009;12:309-318.32. van der Hooft CS, Schoofs MW, Ziere G,et al. Inappropriate benzodiazepine usein older adults and the risk of fracture. BrJ Clin Pharmacol 2008;66:276-282.33. Senanarong V, Cummings JL, FairbanksL, et al. Agitation in Alzheimer’s diseaseis a manifestation of frontal lobe dys-function. Dement Geriatr Cogn Disord2004;17:14-20.34. Pollock BG, Mulsant BH, Rosen J, et al.A double-blind comparison of citalopramand risperidone for the treatment ofbehavioral and psychotic symptomsassociated with dementia. Am J GeriatrPsychiatry 2007;15:942-952.35. Passmore MJ. Sublingual sufentanil forincident pain and dementia-relatedresponse agitation. Int Psychogeriatr2011;23:844-846.Therapeutic approaches in the management of behavioral and psychological symptoms of dementia in the elderly 95www.bcmj.org VOL. 55 NO. 2, MARCH 2013 BC MEDICAL JOURNAL